Full-Time
Senior Backend Engineer
Posted on 6/27/2024
Asimov
51-200 employees
Synthetic biology solutions for biopharmaceuticals
Senior, Expert
Boston, MA, USA
Hybrid position.
- 6+ years of experience in software development.
- Technical expertise in Python 3, Strawberry, SQLAlchemy, GraphQL, Elasticsearch, Docker.
- Ability to navigate the ambiguity of building something that is first-of-its-kind.
- Multiple years of experience building and scaling systems to production-level workloads.
- Sound technical judgment that considers quality, performance, and product stage.
- Passion for joining a startup where autonomy, passion to learn, and excitement to engineer biology take precedence over process and ego.
- Design, build, and maintain software tools that are used by bioengineers to advance the design and manufacture of biologics and gene therapies.
- Directly shape the software architecture and be involved in the long-term product direction.
- Work with a modern backend stack (Python 3, Strawberry, SQLAlchemy).
- Develop data models and schemas for the complex domain of biology.
- Be part of an on-call rotation to support the software you’ve helped develop.
- Interface directly with members of the synthetic biology team to identify and prioritize potential improvements to software systems.
- Contribute to Asimov’s technology platform, direction, and culture.
- Connect with teammates on-site in our Fenway office 3 days per week.
Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their main products include cloud-based software that helps clients in the biopharmaceutical industry design, simulate, and optimize genetic systems, along with engineered GMP host cells for therapeutic uses. Asimov stands out from competitors by offering a unique guarantee on their high titer cell lines for monoclonal antibodies, promising '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
6 month growth
↑ 2%1 year growth
↑ 16%2 year growth
↑ 78%
Simplify's Take
What believers are saying
- The launch of the LV Edge Producer System promises scalable, reproducible, and low-cost production of lentivirus, potentially unlocking larger therapeutic applications.
- The establishment of Asimov Labs with The Foundry team enhances Asimov's R&D capabilities, driving forward advanced genetic design and engineering.
- Asimov's innovative approach to synthetic biology and biocomputing could lead to significant breakthroughs in therapeutic development and manufacturing.
What critics are saying
- The complexity of integrating The Foundry's team and infrastructure into Asimov could pose operational challenges.
- The reliance on advanced genetic and computational tools may require substantial ongoing investment in R&D, impacting financial stability.
What makes Asimov unique
- Asimov's LV Edge System offers a unique fully stable cell line development service, eliminating GMP plasmid costs and reducing process complexity, unlike traditional multi-plasmid transfection methods.
- The integration of The Foundry's advanced genetic design capabilities from MIT and the Broad Institute positions Asimov at the forefront of genetic engineering innovation.
- Asimov's focus on combining cellular, genetic, and computational tools to enable next-generation therapeutics sets it apart from competitors who may specialize in only one of these areas.
Help us improve and share your feedback! Did you find this helpful?